Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Eloy E Ordaya; Elena Beam; Joseph D Yao; Raymund R Razonable; Paschalis Vergidis

doi:10.1093/ofid/ofac283

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Open Forum Infect Dis. 2022 Jun 7;9(7):ofac283. doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.

Authors

Eloy E Ordaya¹, Elena Beam¹, Joseph D Yao², Raymund R Razonable¹, Paschalis Vergidis¹

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

Keywords: COVID-19; immunocompromised hosts; monoclonal antibodies; transplant infectious diseases.